At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (25mg/1000mg and 12.5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)
In Brief
A Phase 1 clinical trial evaluating Empagliflozin/Metformin XR, FDC, Empagliflozin/Metformin XR FDC, and 3 other interventions for Healthy. Completed, enrolled 72 participants across 1 site.
Detailed Summary
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing empagliflozin \& metformin and the single tablets of empagliflozin and metformin when administered singularly.
Study Details
Timeline
Interventions
Experimental: high dose empagliflozin/metformin XR, FDC tablet
Experimental: low dose empagliflozin/metformin XR, FDC tablet
Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
Active Comparator: 1x empagliflozin/2x metformin XR tablets
Active Comparator: 1x empagliflozin/3x metformin XR tablets
Active Comparator: 1x empagliflozin/2x metformin XR tablets